CN106668237A - Medicine for treating optic atrophy - Google Patents
Medicine for treating optic atrophy Download PDFInfo
- Publication number
- CN106668237A CN106668237A CN201610716653.9A CN201610716653A CN106668237A CN 106668237 A CN106668237 A CN 106668237A CN 201610716653 A CN201610716653 A CN 201610716653A CN 106668237 A CN106668237 A CN 106668237A
- Authority
- CN
- China
- Prior art keywords
- parts
- medicine
- optic atrophy
- decocts
- folium sennae
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000001749 optic atrophy Diseases 0.000 title claims abstract description 28
- 239000003814 drug Substances 0.000 title claims abstract description 23
- 229940079593 drug Drugs 0.000 title abstract description 4
- 235000003332 Ilex aquifolium Nutrition 0.000 claims abstract description 11
- 235000002296 Ilex sandwicensis Nutrition 0.000 claims abstract description 11
- 235000002294 Ilex volkensiana Nutrition 0.000 claims abstract description 11
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 11
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 11
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 11
- 239000000463 material Substances 0.000 claims abstract description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000009636 Huang Qi Substances 0.000 claims description 9
- 241001092483 Prinsepia Species 0.000 claims description 9
- 235000008997 Prinsepia uniflora Nutrition 0.000 claims description 9
- 241000220317 Rosa Species 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000012467 final product Substances 0.000 claims description 6
- 239000000706 filtrate Substances 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000004185 liver Anatomy 0.000 abstract description 14
- 239000008280 blood Substances 0.000 abstract description 13
- 210000004369 blood Anatomy 0.000 abstract description 13
- 230000004438 eyesight Effects 0.000 abstract description 8
- 210000003734 kidney Anatomy 0.000 abstract description 6
- 230000004087 circulation Effects 0.000 abstract description 3
- 206010062717 Increased upper airway secretion Diseases 0.000 abstract description 2
- 208000026435 phlegm Diseases 0.000 abstract description 2
- 230000004304 visual acuity Effects 0.000 abstract description 2
- 241000045403 Astragalus propinquus Species 0.000 abstract 2
- 241000209035 Ilex Species 0.000 abstract 2
- 235000004789 Rosa xanthina Nutrition 0.000 abstract 2
- 241000109329 Rosa xanthina Species 0.000 abstract 2
- 241000157352 Uncaria Species 0.000 abstract 2
- 235000006533 astragalus Nutrition 0.000 abstract 2
- 201000010099 disease Diseases 0.000 description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 16
- 210000003733 optic disk Anatomy 0.000 description 7
- 230000007812 deficiency Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- 230000000007 visual effect Effects 0.000 description 5
- 208000010412 Glaucoma Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000000686 essence Substances 0.000 description 4
- 239000000835 fiber Substances 0.000 description 4
- 210000001328 optic nerve Anatomy 0.000 description 4
- 210000001525 retina Anatomy 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000004456 color vision Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000007917 intracranial administration Methods 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 208000003435 Optic Neuritis Diseases 0.000 description 2
- 201000010183 Papilledema Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000035568 catharsis Effects 0.000 description 2
- 230000006735 deficit Effects 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 238000002577 ophthalmoscopy Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000002207 retinal effect Effects 0.000 description 2
- WTPPRJKFRFIQKT-UHFFFAOYSA-N 1,6-dimethyl-8,9-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione;1-methyl-6-methylidene-8,9-dihydro-7h-naphtho[1,2-g][1]benzofuran-10,11-dione Chemical compound O=C1C(=O)C2=C3CCCC(=C)C3=CC=C2C2=C1C(C)=CO2.O=C1C(=O)C2=C3CCC=C(C)C3=CC=C2C2=C1C(C)=CO2 WTPPRJKFRFIQKT-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- -1 B12 Chemical compound 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010009189 Cinchonism Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 206010020741 Hyperpyrexia Diseases 0.000 description 1
- 208000010038 Ischemic Optic Neuropathy Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- 206010030924 Optic ischaemic neuropathy Diseases 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 206010033708 Papillitis Diseases 0.000 description 1
- 206010033712 Papilloedema Diseases 0.000 description 1
- 201000007737 Retinal degeneration Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000022971 Tuberculous meningitis Diseases 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 201000011101 acute retrobulbar neuritis Diseases 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 201000007058 anterior ischemic optic neuropathy Diseases 0.000 description 1
- 206010003074 arachnoiditis Diseases 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- YTLQFZVCLXFFRK-UHFFFAOYSA-N bendazol Chemical compound N=1C2=CC=CC=C2NC=1CC1=CC=CC=C1 YTLQFZVCLXFFRK-UHFFFAOYSA-N 0.000 description 1
- 229950000900 bendazol Drugs 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000003161 choroid Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 210000004220 fundus oculi Anatomy 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 208000014188 hereditary optic neuropathy Diseases 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229960005321 mecobalamin Drugs 0.000 description 1
- 208000001223 meningeal tuberculosis Diseases 0.000 description 1
- JEWJRMKHSMTXPP-BYFNXCQMSA-M methylcobalamin Chemical compound C[Co+]N([C@]1([H])[C@H](CC(N)=O)[C@]\2(CCC(=O)NC[C@H](C)OP(O)(=O)OC3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)C)C/2=C(C)\C([C@H](C/2(C)C)CCC(N)=O)=N\C\2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O JEWJRMKHSMTXPP-BYFNXCQMSA-M 0.000 description 1
- 235000007672 methylcobalamin Nutrition 0.000 description 1
- 239000011585 methylcobalamin Substances 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 201000002166 optic papillitis Diseases 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 201000010473 primary optic atrophy Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 244000132619 red sage Species 0.000 description 1
- 208000022670 retrobulbar neuritis Diseases 0.000 description 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960003232 troxerutin Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 230000004382 visual function Effects 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/62—Nymphaeaceae (Water-lily family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/481—Astragalus (milkvetch)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/482—Cassia, e.g. golden shower tree
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
- A61K36/738—Rosa (rose)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a medicine for treating optic atrophy. The medicine is prepared from the following raw medicinal materials in parts by weight: 7 parts of lotus leaves, 18 parts of uncaria hooks, 6 parts of nux prinsepiae, 10 parts of holly leaves, 12 parts of roses, 4 parts of astragalus membranaceus and 4 parts of folium sennae. According to the medicine provided by the invention, the holly leaves enrich yin and tonify kidneys, the roses disperse stagnated liver qi to relieve depression, the lotus leaves send up the lucid yang, the uncaria hooks clear away heat and calm the liver, the nux prinsepiae nourish the liver to improve visual acuity, the astragalus membranaceus replenish qi and nourish blood, and the folium sennae dissipate phlegm for resuscitation and resolve dampness and promote circulation of qi. The medicines are combined in use to achieve the functions of enriching yin and tonifying kidneys, dispersing stagnated liver qi to relieve depression, replenishing qi and nourishing blood and dredging collaterals and improving acuity of vision. Clinical experiments verify that the medicine provided by the invention can safely and effectively treat optic atrophy.
Description
Technical field
The present invention relates to a kind of Chinese medicine, and in particular to a kind of medicine for treating optic atrophy.
Background technology
Optic atrophy is not the title of a disease, and refers to that any disease causes retinal ganglial cells and its axle
Happen suddenly sick change, cause that optic nerve all attenuates it is a kind of formed to learn change, typically betide retina to corpus geniculatum lateral it
Between Ganglion cell axon denaturation, with visual function damage and pallor papillae as principal character.Optic atrophy is optic nerve
The final result of disease damage, shows as the denaturation and disappearance of optic nerve fiber, and visual field change occurs in conduction function obstacle, and eyesight subtracts
Move back and lose.It is generally divided into primary and the class of Secondary cases two.The visible nipple color that regards of funduscopy is as yellowish or pale asphyxia, boundary
Fuzzy, physiological depression disappears, and blood vessel attenuates.Its cause of disease, it is however generally that, children's optic atrophy is scorching with brain tumor or encephalic
It is more caused by disease；Adolescent patients are based on heredity；Aged patients mostly then are optic neuritis or neurotrosis；The elderly Ze Chang with
Glaucoma or the vascular cause of disease are relevant.This disease is rather refractory, and modern Western medicine there is no so far specific short.
This disease belongs to " glaucoma " category in traditional Chinese medicine.
The cause of disease
1. primary optic atrophy
Often because of retrobulbar neuritis, hereditary optic neuropathy（Leber is sick）, orbital internal tumor compressing, wound, the original such as neurotoxin
Because caused.These pathologies occur after ball.
2. secondary optic atrophy
Common are the dynamic film resistance of papillitis optica, papilloedema, retina train of thought inflammation, retinal pigment degeneration, retinal centre
Plug, cinchonism, anterior ischemic optic neuropathy, glaucoma etc..
3. caused by intracranial lesion
By intracranial inflammation, such as tubercular meningitis or chiasmal arachnoiditis can cause descending optic atrophy, and such as inflammation is climing
It is extended down to and then can behave as secondary optic atrophy depending on nipple.Intracranial pressure produced by ICT is raised, and can be caused regarding breast
Cephaledema, then forms secondary optic atrophy.
Clinical manifestation
Main performance hypopsia and optic disk are in canescence or pale.Crack shape is may occur in which during optic disk peripheral nerve fibrage disease damage
Or wedge-shaped defect, the former becomes compared with black, is layer of retina,pigmentary exposure；The latter, in more red, is choroid exposure.If damaged
Evil betides lower edge area on optic disk, then more easy to identify, because area's nerve fibre layer is especially thickened, if disease damage is away from optic disk area,
Due to these regional nerve fibers lead it is thinning, then be difficult find.Nerve fibre layer is often pointed out around optic disk with focal atrophy
There is pathology, be that nerve fibre layer is thinning caused in the area.
Although conventional funduscopy can find, it is easier to check with taking pictures without red smooth ophthalmoscope and eyeground.Optic disk is little
Blood vessel is usually 9~10, if optic atrophy, these thin vessels numbers will be reduced.Still see that arteria retina becomes simultaneously
Thin and narrow, obturation.
Optic atrophy is divided to two kinds of primary and Secondary cases：The former optic disk boundary is clear, and physiological depression and sieve plate are visible；Afterwards
Person's boundary is obscured, and physiological depression and sieve plate are invisible.
Drug therapy
1. it is conventional including neurotrophy medicine such as vitamin B1, B12, ATP and coacetylase etc., vasodilator agent and activate blood circulation and disperse blood clots
The such as Yan acid of medicine class, dibazol, vitamin E, troxerutin, compound Danshen Root etc..Noted by hyperbaric oxygen, ECP acupuncture point in recent years
654-2 etc. is penetrated achieved with certain effect.
2. Chinese medicine is started with marrow, whole body therapeutic, makes illness start to take a turn for the better, and human body recovers normal physiological function.
Medicinal material involved in the present invention is visible to be recorded in《Chinese book on Chinese herbal medicine》.
The content of the invention
The present invention is intended to provide a kind of medicine for treating optic atrophy, by selecting suitable medicinal material and its matching somebody with somebody
Than reaching the purpose for safely and effectively curing optic atrophy.
In order to achieve the above object, the present invention is employed the following technical solutions：
A kind of medicine for treating optic atrophy, it is characterised in that it is prepared by the raw medicinal material of following weight proportion
Form：7 parts of lotus leaf, 18 parts of yncaria stem with hooks hook, 6 parts of Hedge Prinsepia Nut, 10 parts of holly leaf, 12 parts of rose, 4 parts of the Radix Astragali, 4 parts of folium sennae.
Beneficial effect of the present invention is illustrated with reference to theories of Chinese materia medica：
It has been recognised by the inventors that its interpretation of the cause, onset and process of an illness of optic atrophy is as follows.Kidney deficiency：Or because of native endowment deficiency, or because of hyperpyrexia impairment of yin, or because long
Sick overstrain, cause deficiency of kidney-YIN, asthenia of essence and blood, water files to nourish wood, flaring up of deficient fire, hinders Tianjin consumption liquid, and essence and blood is unable to sending nutrient upward to eye and causes green grass or young crops
It is blind.Liver is evil：Many because feelings will is unsuccessful, the angry impariment of the liver, stagnation of liver qi, catharsis is neglected one's duty, functional activity of QI being not smooth, and blood is with the obstruction of the circulation of vital energy or former because of other
Send out because causing mechanism of qi to rise, catharsis function mistakes degree can also cause stagnation of liver qi, mesh network blocks, body fluid is not all right, it is impossible to moisten and support in mesh
Morbidity.Deficiency of qi and blood：More because native endowment is not enough, or eating and drinking without temperance, overwork, weakness of the spleen and the stomach, the biochemical weary source of qi and blood, operation
It is powerless.The deficiency of vital energy then blurring of vision, the deficiency of blood then loss of nutrient of eyes, can cause glaucoma.Qi depression to blood stasis：Or because of head injury, mesh system receives
Damage, or feelings will is not relaxed, and during pent-up long, or due to pathogen usually intruding into collateral in protracted disease, causes stagnation of blood stasis train of thought, vital essence to go up up to caused by mesh.Therefore
Nourishing YIN for benefiting the kidney, liver soothing and depression relief, benefiting qi and nourishing blood, dredging collateral improving eyesight are then taken in treatment.
The present invention is used：Holly leaf nourishing YIN for benefiting the kidney；Rose liver soothing and depression relief；Lotus leaf sending up the lucid yang；The heat-clearing of yncaria stem with hooks hook is put down
Liver；Hedge Prinsepia Nut nourishes the liver to improve visual acuity；Radix Astragali benefiting qi and nourishing blood；Folium sennae dissipating phlegm for resuscitation, dampness elimination promoting the circulation of qi.All medicines share, reaches nourishing YIN for benefiting the kidney, relaxes
Liver solution is strongly fragrant, benefiting qi and nourishing blood, the effect of dredging collateral improving eyesight.
Beneficial effects of the present invention are illustrated with reference to clinical laboratory data：
1st, physical data
Inventor collects altogether 39 optic atrophies between in January, -2015 in January, 2012.It is randomly divided into：Treatment group 20,
Control group 19.Wherein treatment group man 14, female 6,32~58 years old age, the course of disease 2 months~3 years；Control group man 14, female
5, between 35~60 years old age, the course of disease 1 month~5 years.There was no significant difference for the data such as two groups of sexes, age, courses of disease, with can
Compare property.
Diagnostic criteria
1. vision impairment；
2. the visual field changes；
3. Fundus oculi changes are particularly optic nerve color, morphologic change
4. clear and definite related history.
1. inclusive criteria meets diagnostic criteria；2. age 18~70 years old；3. compliance is good；4. informed consent is voluntarily signed
Book.
Exclusion standard 1. gestation, women breast-feeding their children；2. severe cardiac, lung, liver, renal disease patient are suffered from；3. there are other essences
Refreshing systemic disease, it is impossible to partner treatment person；4. the patient of Jing other drugs treatment after falling ill.
2nd, treatment method
, according to capsule obtained in specific embodiment 3,3 times a day for the oral present invention for the treatment of group.Treatment 2 months.
The oral mecobalamin capsules of control group, each 0.5mg, 3 times a day.Treatment 2 months.
3rd, criterion of therapeutical effect and treatment results
3.1 criterions of therapeutical effect
1. fully recover：Symptom disappears, and eyesight is more than 1.0, and the visual field and colour vision are normal, and there is certain improvement on eyeground；
2. it is effective：Symptom improves, and eyesight increases more than 1 row, and the visual field and colour vision have certain improvement, but eyeground improves unobvious；
3. it is invalid：Before and after treatment, symptom, eyesight, the visual field, colour vision and eyeground have no change.
3.2 treatment statistics are shown in Table 1.
1 two groups of comparitive studies of table
| Group | n | Recovery from illness | Effectively | It is invalid | Total effective rate (%) | Obvious adverse reaction example |
| Treatment group | 20 | 8 | 11 | 1 | 95% | 0 |
| Control group | 19 | 6 | 10 | 3 | 84% | 0 |
It can be seen that, the obtained medicine of the present invention can safely and effectively treat optic atrophy, and cure rate is high.
Specific embodiment
In order to more fully understand and implementing the present invention, with reference to specific embodiment the present invention is further illustrated.
Embodiment 1
Weigh：7 grams of lotus leaf, 18 grams of yncaria stem with hooks hook, 6 grams of Hedge Prinsepia Nut, 10 grams of holly leaf, 12 grams of rose, 4 grams of the Radix Astragali, folium sennae 4
Gram；Plus 8 times of amount water, decoct 1.5 hours, filter；Filter residue adds 6 times of amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120
Gram, obtain final product the decoction for meeting one day consumption of adult normal.
For treating optic atrophy.Orally, daily once.
Embodiment 2
Weigh：7 grams of lotus leaf, 18 grams of yncaria stem with hooks hook, 6 grams of Hedge Prinsepia Nut, 10 grams of holly leaf, 12 grams of rose, 4 grams of the Radix Astragali, folium sennae 4
Gram；Plus 10 times of amount water, decoct 2 hours, filter；Filter residue adds 8 times of amount water, decocts 1.5 hours, filters；Merging filtrate, concentration is done
Dry, packaging obtains final product the powder for meeting one day consumption of adult normal.
For treating optic atrophy.Orally, take twice sooner or later per bu.
Embodiment 3
Weigh：7 grams of lotus leaf, 18 grams of yncaria stem with hooks hook, 6 grams of Hedge Prinsepia Nut, 10 grams of holly leaf, 12 grams of rose, 4 grams of the Radix Astragali, folium sennae 4
Gram；Plus 6 times of amount water, decoct 3 times, decoct 1 hour every time, merge decoction liquor, concentration is dried, and loads capsule shells, obtains final product and meets just
The capsule of one day consumption of normal adult.
For treating optic atrophy.Orally, take for three times per the bu morning, noon and afternoon.
Claims (4)
1. a kind of medicine for treating optic atrophy, it is characterised in that it is by the raw medicinal material system of following weight proportion
It is standby to form：7 parts of lotus leaf, 18 parts of yncaria stem with hooks hook, 6 parts of Hedge Prinsepia Nut, 10 parts of holly leaf, 12 parts of rose, 4 parts of the Radix Astragali, 4 parts of folium sennae.
2. the as claimed in claim 1 medicine for being used to treat optic atrophy, it is characterised in that its preparation method is：Weigh：
7 parts of lotus leaf, 18 parts of yncaria stem with hooks hook, 6 parts of Hedge Prinsepia Nut, 10 parts of holly leaf, 12 parts of rose, 4 parts of the Radix Astragali, 4 parts of folium sennae；Plus 8 times of amounts
Water, decocts 1.5 hours, filters；Filter residue adds 6 times of amount water, decocts 1 hour, filters；Merging filtrate, is concentrated into 120 parts, obtains final product pan-fried
Agent；Above-mentioned part each means weight portion.
3. the as claimed in claim 1 medicine for being used to treat optic atrophy, it is characterised in that its preparation method is：Weigh：
7 parts of lotus leaf, 18 parts of yncaria stem with hooks hook, 6 parts of Hedge Prinsepia Nut, 10 parts of holly leaf, 12 parts of rose, 4 parts of the Radix Astragali, 4 parts of folium sennae；Plus 10 times of amounts
Water, decocts 2 hours, filters；Filter residue adds 8 times of amount water, decocts 1.5 hours, filters；Merging filtrate, concentration is dried, and packaging is obtained final product
Powder；Above-mentioned part each means weight portion.
4. the as claimed in claim 1 medicine for being used to treat optic atrophy, it is characterised in that its preparation method is：Weigh：
7 parts of lotus leaf, 18 parts of yncaria stem with hooks hook, 6 parts of Hedge Prinsepia Nut, 10 parts of holly leaf, 12 parts of rose, 4 parts of the Radix Astragali, 4 parts of folium sennae；Plus 6 times of amounts
Water, decocts 3 times, decocts 1 hour every time, merges decoction liquor, and concentration is dried, and loads capsule shells, obtains final product capsule；Above-mentioned part is equal
Refer to weight portion.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716653.9A CN106668237A (en) | 2016-08-25 | 2016-08-25 | Medicine for treating optic atrophy |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610716653.9A CN106668237A (en) | 2016-08-25 | 2016-08-25 | Medicine for treating optic atrophy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106668237A true CN106668237A (en) | 2017-05-17 |
Family
ID=58840001
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610716653.9A Pending CN106668237A (en) | 2016-08-25 | 2016-08-25 | Medicine for treating optic atrophy |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106668237A (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634195A (en) * | 2003-12-30 | 2005-07-06 | 吉林省第二荣复军人医院 | Eye disease treating medicine |
| CN101264230A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating optic atrophy and preparation thereof |
| CN104306546A (en) * | 2014-08-15 | 2015-01-28 | 河南科技大学 | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition |
-
2016
- 2016-08-25 CN CN201610716653.9A patent/CN106668237A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1634195A (en) * | 2003-12-30 | 2005-07-06 | 吉林省第二荣复军人医院 | Eye disease treating medicine |
| CN101264230A (en) * | 2008-04-25 | 2008-09-17 | 北京中泰天和科技有限公司 | Chinese medicinal composition for treating optic atrophy and preparation thereof |
| CN104306546A (en) * | 2014-08-15 | 2015-01-28 | 河南科技大学 | A traditional Chinese medicine composition used for treating optic atrophy, and decoctions, pills and powder of the composition |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210169779A1 (en) | Ophthalmic drug preparation and uses thereof | |
| CN102813780A (en) | Chinese herbal medicinal compound preparation used for treating macular degeneration of old people and preparation method thereof | |
| CN104971304A (en) | Xerophthalmia treatment medicine | |
| CN104906220B (en) | A kind of Chinese medicine for treating herpes zoster and herpes simplex keratitis | |
| CN105168739B (en) | A kind of treat hypertension, hyperlipidemia, hyperglycemia and the compositions of resisting fatigue improving eyesight | |
| CN102309632B (en) | Application of pharmaceutical composition in preparation of pharmaceuticals for treating complications of diabetes | |
| CN104189819A (en) | Traditional Chinese medicine preparation for regulating emotional health | |
| CN107789430A (en) | A kind of application of Chinese medicine composition in preventing/treating macular degeneration disease medicine is prepared | |
| CN107648397B (en) | Traditional Chinese medicine composition for treating liver-kidney yin deficiency and preparation method and application thereof | |
| CN106668237A (en) | Medicine for treating optic atrophy | |
| CN104998087A (en) | Traditional Chinese medicine composition for treating primary hypertension and preparing method of traditional Chinese medicine composition | |
| CN106668240A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN112294963A (en) | Pharmaceutical composition for treating age-related macular degeneration | |
| CN104740334A (en) | Traditional Chinese medicinal composition for preventing and treating cataract and preparation method of traditional Chinese medicinal composition | |
| CN104324139B (en) | A kind of pharmaceutical composition treating xerophthalmia | |
| CN104306579B (en) | A kind of Chinese medicine for treating deficiency of yin and stagnation of blood diabetic retinopathy and preparation method and application | |
| CN102940753A (en) | Pills for treating glaucoma and preparation method | |
| CN106581221A (en) | Pharmaceutical composition for treating vitreous opacity | |
| CN106728678A (en) | The herbal mixture and preparation method of hypoglycemic | |
| CN106619816A (en) | Pharmaceutical composition for treating optic atrophy | |
| CN106491730A (en) | A kind of treat Chinese medicine composition of glaucoma and preparation method thereof | |
| CN104800465A (en) | Traditional Chinese medicine composition for treating stagnation of qi due to depression of liver type primary glaucoma | |
| CN105148118B (en) | A kind of Chinese medicine composition medicament and preparation method thereof for treating xerophthalmia | |
| CN1331500C (en) | Chinese medicine for treating ocular funcus hemorrhage caused by yin deficiency, liver sthenia, heat impairing collaterals and preparation method | |
| CN104771638A (en) | Traditional Chinese medicine composition for treating optic atrophy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170517 |